Closing out strong, join MSK radiation oncologist Dr. Amy Xu at #ASCO26 as she presents results from a phase II study evaluating genomically personalized radiation dose de-escalation in patients with pathogenic ATM mutations.
š Tuesday, June 2 | 10:39 a.m. CDT
Learn more: https://bit.ly/4x1m1ST
